Clinical Trials Browser

Phase 1/2 × Panitumumab × 90 days × Clear all

NCT03384238 2026-03-17

Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

Phase 1/2 Recruiting

Gastrointestinal

Pancreatic Adenocarcinoma

NCT03510208 2026-02-09

Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery

Phase 1/2 Recruiting

Brain Neoplasms, Glioma